http://sg.news.yahoo.com/041128/1/3ovex.html
Sunday November 28, 1:21 PM
Paralyzed woman walks again after stem cell
therapy
A South Korean woman paralyzed for 20 years is walking again after scientists
say they repaired her damaged spine using stem cells derived from
umbilical cord blood. Hwang Mi-Soon, 37, had been bedridden since damaging her
back in an accident two decades ago. Last week her eyes glistened with tears as
she walked again with the help of a walking frame at a press conference where
South Korea researchers went public for the first time with the results of their
stem-cell therapy.
They said it was the world's first published case in which a patient with spinal
cord injuries had been successfully treated with stem cells from
umbilical cord blood. Though they cautioned that more research was needed and
verification from international experts was required, the South Korean
researchers said Hwang's case could signal a leap forward in the treatment of
spinal cord injuries.
The use of stem cells from cord blood could also point to a way to side-step the
ethical dispute over the controversial use of embryos in embryonic
stem-cell research. "We have glimpsed at a silver lining over the horizon," said
Song Chang-Hoon, a member of the research team and a professor at Chosun
University's medical school in the southwestern city of Kwangju. "We were all
surprised at the fast improvements in the patient."
Under TV lights and flashing cameras, Hwang stood up from her wheelchair and
shuffled forward and back a few paces with the help of the frame at the
press conference here on Thursday. "This is already a miracle for me," she said.
"I never dreamed of getting to my feet again."
Medical research has shown stem cells can develop into replacement cells for
damaged organs or body parts. Unlocking that potential could see cures for
diseases that are at present incurable, or even see the body generate new organs
to replace damaged or failing ones. So-called "multi-potent" stem cells -- those
found in cord blood -- are capable of forming a limited number of specialized
cell types, unlike the more versatile "undifferentiated" cells that are derived
from embryos.
However, these stem cells isolated from umbilical cord blood have emerged as an
ethical and safe alternative to embryonic stem cells. Clinical trials with
embryonic stem cells are believed to be years away because of the risks and
ethical problems involved in the production of embryos -- regarded as living
humans by some people -- for scientific use.
In contrast, there is no ethical dimension when stem cells from umbilical cord
blood are obtained, according to researchers. Additionally, umbilical cord blood
stem cells trigger little immune response in the recipient as embryonic stem
cells have a tendency to form tumors when injected into animals or human beings.
For the therapy, multi-potent stem cells were isolated from umbilical cord
blood, which had been frozen immediately after the birth of a baby and
cultured for a period of time. Then these cells were directly injected to the
damaged part of the spinal cord.
"Technical difficulties exist in isolating stem cells from frozen umbilical cord
blood, finding cells with genes matching those of the recipient and selecting
the right place of the body to deliver the cells," said Han Hoon, president of
Histostem, a government-backed umbilical cord blood bank in Seoul.
Han teamed up with Song and other experts for the experiment. They say that more
experiments are required to verify the outcome of the landmark therapy. "It is
just one case and we need more experiments, more data," said Oh Il-Hoon, another
researcher.
"I believe experts in other countries have been conducting similar experiments
and accumulating data before making the results public."